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Background: The aim of this study was to assess the severity of pain and its impact on the quality of life (QoL) in
untreated patients with head and neck squamous cell carcinoma (HNSCC).
Methods: A study group of 127 patients with HNSCC were interviewed before antineoplastic treatment. The
severity of pain was measured using the Brief Pain Inventory (BPI) questionnaire, and the QoL was assessed with
the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC
QLQ-C30) and the head and neck module (QLQ-H&N35).
Results: The mean age of the patients was 57.9 years, and there was a predominance of men (87.4%). The most
frequent site of the primary tumor was the oral cavity (70.6%), and the majority of the patients had advanced
cancers (stages III and IV). QoL in early stage of cancer obtained better scores. Conversely, the patients with
advanced stage cancer scored significantly higher on the symptom scales regarding fatigue, pain, appetite loss and
financial difficulties, indicating greater difficulties. Regard to the severity of pain, patients with moderate-severe pain
revealed a significantly worse score than patients without pain.
Conclusions: The severity of pain is statistically related to the advanced stages of cancer and directly affects the
QoL. An assessment of the quality of life and symptoms before therapy can direct attention to the most important
symptoms, and appropriate interventions can then be directed toward improving QoL outcomes and the response
to treatment.Background
Head and neck cancer (HNC) comprises a group of
tumors that arise in the oral cavity, pharynx and larynx.
It is the 6th most common cancer worldwide, account-
ing for 6% of cancer cases. Approximately 40% of
these tumors occur in the oral cavity, 15% occur in the
pharynx, and 25% occur in the larynx; in 90% of the
cases, the most common histologic type is squamous
cell carcinoma [1,2].
Pain is one of the several symptoms of cancer that create
a poor quality of life (QoL) because pain affects physical
functions and has an emotional impact [3-5]. In HNC,* Correspondence: gouveasa@yahoo.com.br
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reproduction in any medium, provided the orpain affects the oral functions and is a complaint in ap-
proximately 58% of the patients awaiting treatment and in
30% of the treated patients [4,6]. In a meta-analysis of 52
studies that calculated the prevalence of cancer pain, head
and neck cancer had the highest prevalence of pain, sur-
passing gynecological, gastrointestinal, lung and breast
tumors [7].
The complaint of pain has been reported in all clinical
stages of oral cancer, with 88.1% of the cases occurring
in stages III-IV. Some studies have shown a correlation
between pain and tumor staging, with pain being the
initial symptom in approximately 20% of the patients with
oral squamous cell carcinoma [5,6].
Cancer pain is multidimensional and is directly associ-
ated with QoL [8]. The assessment of QoL has increas-
ingly moved toward a modular approach, which allows for
the evaluation of multiple dimensions of functioning. ALtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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experienced by cancer patients, is supplemented by a site-
or treatment-specific module that assesses difficulties
unique to that particular type of cancer or treatment.
Studies have confirmed that both general and site-specific
measures contribute to obtaining important information
concerning QoL [9].
For cancer patients, pain and symptom control are the
best predictors of overall QoL scores because the effects
of unrelieved pain and poorly managed symptoms have
been shown to interfere with the activities of daily living,
mood, mobility, and independence. Therefore, when the
control of symptoms is not attended to, the QoL tends to
be reduced [8,10]. Additionally, studies on the intensity of
pain and QoL among patients with HNC before treatment
are lacking.
We hypothesized that patients with HNC who experi-
enced moderate to severe pain before antineoplastic treat-
ment would report more interference with QoL scores
than those patients without pain. Therefore, the purpose
of this study was to assess pain severity and its impact
on the QoL in untreated patients with head and neck
squamous cell carcinoma (HNSCC), and assess QoL of
these patients with respect to pain severity, clinical stage
of the primary tumor, and lymph nodes involvement.
Methods
Patients
This study is prospective and controlled and it was ap-
proved by the Research Ethics Committee of the Espirito
Santo Federal University (Protocol n° 99.242/2012). We
interviewed 127 outpatients with primary head and
neck squamous cell carcinoma consecutively who had
undergone medical examinations in 2012 at the Santa
Rita de Cassia Hospital-AFECC, Vitoria, ES, Brazil. The
cancer patients were distributed into groups with no
pain (N = 52), mild pain (N = 47), and moderate to se-
vere pain (N = 28). Inclusion criteria were patients with
untreated HNSCC aged over 18 years and both gender.
The exclusion criteria were patients who had already
been treated for HNSCC, had recurrent malignant dis-
ease, were unable to speak Portuguese or had a func-
tional status sufficiently impaired to prevent answering
the questionnaires. Clinical data (gender, age, tobacco
and alcohol consumption, tumor location and tumor
stage) were obtained from medical records.
Assessments
The pain was measured using the item of “average pain”
during the last 24 hours in the Brief Pain Inventory (BPI)
[11], which was validated in the Brazilian population
[12]. The pain scores were categorized into three groups
according to the BPI average pain: no pain (0), mild pain
(1–4), and moderate (5–6) to severe (7–10) pain [13].The BPI asks patients to rate their pain intensity and
pain interference (with general activities, mood, walking
ability, normal work, relationship with others, sleep, and
enjoyment of life) on an 11-point scale ranging from 0 (no
pain/no interference) to 10 (as bad as you can imagine/
complete interference) [11].
The QoL was assessed with the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire Core-30 (EORTC QLQ-C30) version 3.0
[14], which was validated in the Brazilian population [15].
This is a 30-item questionnaire that consists of 5 func-
tional scales (physical, role, cognitive, emotional, and social
functioning), 3 symptom scales (fatigue, pain, and nausea
and vomiting), a global health status/QoL scale, and a num-
ber of single items assessing additional symptoms com-
monly reported by patients with cancer (dyspnea, loss of
appetite, insomnia, constipation, diarrhea, and financial
difficulties). The patients were asked to rate each item on
a 4-point scale and the global health status/QoL scale item
on a 7-point scale [16].
The Quality of Life Questionnaire Head and Neck
Cancer Module (EORTC QLQ-H&N35) [17] has 35 spe-
cific questions concerning problems attributed to HNC
and its treatment-related side effects. There are 7 scaled
answers for pain, swallowing, sensibility, speech, eating in
a social setting, social contact, and sexuality. In addition,11
individual topics were evaluated taking into account the
anatomic site, symptoms, and treatment (dental problems,
mouth opening, dry mouth, poor salivation, coughing,
sense of illness, analgesic use, nutrition difficulties, gastric
tube, and weight loss or gain) [17].
All scales and single items were linearly transformed
to provide a score ranging from 0 to 100; a high score
on the functional scale and for global quality of life
(QoL) was representative of a high level of functioning
and a high QoL. However, a high score on the symptom
scale represented a high level of symptomatology and
problems [18]. The instruments were filled by patients
with staff assistance.
Statistical analyses
The scores from the EORTC QLQ-C30 and EORTC
QLQ-H&N35 were interpreted according to the EORTC
scoring manual [18]. Internal consistency in the questions
was determined using Cronbach’s α coefficient, which is
used as an indicator of scale reliability. The distribution of
quantitative variables was determined using the mean and
standard deviation (determined as normal or abnormal
using the Kolmogorov-Smirnov test). An association be-
tween the domains and other factors were examined using
nonparametric tests (Mann–Whitney and Kruskal-Wallis
tests). Qualitative variables were analyzed using the Chi
square test or Fisher’s exact test. The statistical software
program SPSS version 17 for Windows (Statistical Package
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data analysis. The level of statistical significance was
accepted at p < 0.05.Results
The main features of our series of 127 patients with
HNSCC are summarized in Table 1. The mean age of
the patients was 57.9 years (range, 21–89), and there
was predominance of men (87.4%). The most frequent
site of the primary tumor was the oral cavity (70.6%),Table 1 Clinical and epidemiological features (n = 127)
Age (years)
Range 21 – 89












High school or less 98 (77.2)
College or more 29 (22.8)
Primary tumor location

















Abbreviations: T, Tumor size; N, Lymph node involvement.and the majority of the patients had advanced cancers
(stages III and IV).
The reliability coefficients (Cronbach’s α), means, and
SDs for the EORTC QLQ-C30 scales are listed in Table 2.
The reliability coefficient for most of the scales ranged from
0.73 to 0.89, indicating satisfactory internal consistency,
while nausea/vomiting (NV) had a moderate coefficient
alpha of 0.67. Only the cognitive functioning scale (CF)
presented a lower coefficient (0.31). Reliability coefficients,
means, and SDs for the EORTC QLQ-H&N35 are listed
in Table 3. Each of the scales demonstrated a high α coeffi-
cient (>0.70), except for the speech scale (HNSP) and the
social contact scale (HNSC), both of which had coeffi-
cients equal to 0.68, which is considered moderate.
The reliability of the BPI was evaluated according to
the internal consistency (Cronbach’s α coefficient). The
mean score of item “average pain” during the last 24
hours in the BPI was 4.1. We separately calculated alpha
coefficients for pain severity and pain interference. The
internal consistency of the pain severity dimension was
0.82 and for the pain interference dimension was 0.92,
indicating a satisfactory internal validity (>0.70).
The comparison of the EORTC QLQ-C30 scales with
the tumor size (T) and lymph node involvement (N) indi-
cated that the patients with an early stage tumor scored
significantly higher in physical functioning (T, p = 0.025;
N, p = 0.024), role functioning (T, p = 0.010; N, p = 0.004)
and social functioning (T, p = 0,035; N, p = 0.002), indicat-
ing better functioning. Conversely, the patients with an
advanced-stage tumor scored significantly higher on theTable 2 Descriptive analyses of the EORT QLQ–C30 items
and reliability analysis
QLQ-C30 Mean(SD) Cronbach’s α
Global quality of life/QoL 65.8 (27.1) 0.81
Functional scales
Physical functioning 80.2 (23.3) 0.73
Role functioning 80.7 (32.3) 0.78
Emotional functioning 64.5 (33.5) 0.85
Cognitive functioning 82.1 (25.0) 0.31
Social functioning 89.8 (23.7) 0.70
Symptom scales
Fatigue 21.7 (28.3) 0.75
Nausea and vomiting 5.5 (15.7) 0.67
Pain 36.1 (38.1) 0.89
Dyspnea 9.1 (23.6) -
Insomnia 36.7 (42.7) -
Appetite loss 31.4 (40.3) -
Constipation 23.8 (38.9) -
Diarrhea 2.1 (11.6) -
Financial difficulties 30.7 (42.9) -
Table 3 Descriptive analyses of the EORT QLQ–H&N35
items and reliability analysis
QLQ–H&N35 Mean (SD) Cronbach’s α
Pain 30.5 (31.0) 0.78
Swallowing 32.3 (34.0) 0.86
Senses problems 15.8 (30.7) 0.85
Speech problems 23.8 (29.6) 0.68
Trouble with social eating 22.6 (28.6) 0.81
Trouble with social contact 11.6 (17.5) 0.68
Less sexuality 23.2 (36.5) 0.98
Teeth 18.1 (35.1) -
Opening mouth 19.9 (35.2) -
Dry mouth 22.0 (36.1) -
Sticky saliva 41.7 (43.4) -
Coughing 23.1 (29.2) -
Felt ill 19.1 (34.7) -
Pain killers 66.9 (47.2) -
Nutritional supplements 5.5 (22.9) -
Feeding tube 0 -
Weight loss 47.2 (50.1) -
Weight gain 14.9 (35.8) -
Table 4 EORTC QLQ–C30 scales and TN stage
T*
T1 T2 T3
(n = 25) (n = 30) (n = 24)
EORTC QLQ-C30 Mean (SD) Mean (SD) Mean (SD)
Emotional functioning 75.6 (27.9) 70.8 (34.1) 53.8 (35.8)
Physical functioning 90.4 (17.2) 84.6 (17.6) 75.2 (25.5)
Role functioning 97.3 (13.3) 79.4 (34.3) 77.7 (36.3)
Cognitive functioning 82.6 (22.8) 85.5 (18.9) 79.1 (28.7)
Social functioning 98.6 (6.6) 91.1 (22.6) 83.3 (23.0)
Global quality of life/QoL 75.6 (19.1) 69.7 (26.5) 60.7 (33.6)
Fatigue 9.3 (16.8) 15.1 (22.3) 25.4 (30.1)
Nausea and Vomiting 3.3 (10.7) 3.3 (9.1) 11.8 (24.8)
Pain 8.0 (16.0) 33.8 (34.3) 45.8 (44.0)
Dyspnea 5.3 (12.4) 6.6 (22.1) 19.4 (33.9)
Insomnia 25.3 (36.3) 32.2 (39.6) 30.5 (43.8)
Appetite loss 17.3 (33.4) 24.4 (40.9) 38.8 (41.3)
Constipation 9.3 (29.0) 25.5 (38,8) 33.3 (43.9)
Diarrhea 0 1.1 (6.0) 5.5 (21.2)
Financial difficulties 12.0 (27.0) 24.4 (40.9) 45.8 (48.9)
*Kruskal-Wallis test, **Mann Whitney test. Abbreviations: T, Tumor size; N, Lymph no
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p = 0.003), pain (T, p < 0.001; N, p = 0.001), appetite loss
(T, p = 0.041; N, p = 0.010) and financial difficulties (T,
p = 0.039; N, p = 0.006), indicating greater difficulties
(Table 4). On the EORTC QLQ-H&N35 scales, the pa-
tients with advanced-stage tumors had significantly higher
scores on pain (T, p < 0.001; N, p < 0.001), swallowing
(T, p < 0.001; N, p < 0.001), social eating (T, p < 0.001; N,
P < 0.001), social contact (T, p = 0.005; N, p < 0.001), teeth
(T, p = 0.046; N, p = 0.001), sticky saliva (T, p < 0.001; N,
p = 0.024), pain killers (T, p < 0.001; N, p = 0.038) and
weight loss (T, p < 0.001; N, p < 0.001), indicating greater
impairment (Table 5).
Significant differences in the EORTC scales were found
with regard to pain intensity. On the EORTC QLQ-C30,
the cancer group without pain had better scores on all of
the functional scales: physical functioning (PF, p < 0.001),
role functioning (RF, p < 0.001), emotional functioning
(EF, p = 0.002), cognitive functioning (CF, p = 0.027), social
functioning (SF, p = 0.002) and global quality of life
(QL, p < 0.001) (Figure 1A). However, with regard to the
symptom scales, the cancer group with moderate-severe
pain indicated greater impairment on the fatigue (FA,
p < 0.001), insomnia (SL, p < 0.001), appetite loss (AP,
p = 0.001) and constipation (CO, p < 0.001) scales (Figure 1B).
The cancer group with mild pain showed greater impair-
ment on the nausea/vomiting (NV, p = 0.045) and finan-
cial difficulties (FI, p < 0.001) scales when compared with
the cancer group with no pain.N**
T4 N0 N+
(n = 48) (n = 43) (n = 84)
Mean (SD) p Mean (SD) Mean (SD) p
60.0 (33.0) 0.085 69.5 (31.0) 54.6 (36.2) 0.039
74.5 (26.1) 0.025 83.8 (21.0) 73.1 (26.1) 0.024
74.3 (33.8) 0.010 86.3 (27.2) 69.7 (38.5) 0.004
81.2 (27.8) 0.938 84.1 (24.1) 78.2 (26.6) 0.158
87.8 (29.1) 0.035 94.0 (19.4) 81.7 (29.0) 0.002
60.9 (26.4) 0.130 70.3 (23.4) 57.1 (31.6) 0.033
30.5 (32.6) 0.012 16.9 (26.5) 31.2 (29.7) 0.003
4.8 (14.9) 0.252 3.9 (13.1) 8.5 (19.7) 0.090
47.2 (38.4) <0.001 27.5 (34.3) 52.7 (39.8) 0.001
7.6 (22.0) 0.124 9.1 (23.9) 9.3 (23.3) 0.816
48.6 (45.5) 0.129 30.5 (39.4) 48.8 (46.7) 0.041
39.5 (41.0) 0.041 25.3 (38.5) 43.4 (41.4) 0.010
25.6 (40.2) 0.127 20.2 (36.2) 31.0 (43.2) 0.135
2.0 (10.6) 0.511 0.7 (5.1) 4.6 (18.6) 0.199
36.8 (44.6) 0.039 22.6 (38.0) 46.5 (47.7) 0.006
de involvement.
Table 5 EORTC QLQ-H&N35 scales and TN stage
T* N**
T1 T2 T3 T4 N0 N+
(n = 25) (n = 30) (n = 24) (n = 48) (n = 43) (n = 84)
EORTC QLQ –H&N35 Mean (SD) Mean (SD) Mean (SD) Mean (SD) p Mean (SD) Mean (SD) p
Pain 7.6 (13.5) 29.4 (26.5) 28.4 (28.2) 44.2 (34.5) <0.001 24.0 (29.2) 43.4 (30.7) <0.001
Swallowing 2.0 (6.0) 32.7 (32.8) 31.2 (33.5) 48.4 (33.3) <0.001 22.8 (32.0) 50.9 (30.1) <0.001
Senses problems 15.3 (33.6) 10.0 (21.2) 16.6 (28.2) 19 (35.4) 0.926 14.6 (30,6) 18.2 (31.2) 0.362
Speech problems 13.7 (25.7) 15.1 (22.5) 30.5 (33.4) 31.2 (31.2) 0.029 20.8 (27.9) 29.7 (32.2) 0.240
Trouble with social eating 2.0 (6.9) 19.1 (26.6) 25.6 (29.8) 34.0 (30.5) <0.001 14.4 (23.5) 38.5 (31.2) <0.001
Trouble with social contact 5.0 (7.2) 7.7 (14.0) 18.8 (20.4) 13.8 (20.1) 0.005 7.4 (10.7) 19.8 (24.2) 0.001
Less sexuality 12.0 (25.2) 16.1 (29.1) 29.1 (43.1) 30.5 (40.5) 0.211 14.0 (29.1) 41.0 (42.9) <0.001
Teeth 4.0 (14.6) 16.6 (34.7) 12.5 (29.1) 29.1 (42.1) 0.046 10.3 (26.8) 33.3 (43.6) 0.001
Opening mouth 1.3 (6.6) 10.0 (27.8) 19.4 (30.9) 36.1 (42.8) <0.001 15.4 (30.3) 28.6 (42.1) 0.112
Dry mouth 25.3 (38.8) 27.7 (37.2) 18.0 (36.7) 18.7 (34.3) 0.416 22.2 (36.7) 21.7 (35.5) 0.946
Sticky saliva 13.3 (27.2) 37.7 (40.8) 34.7 (45.5) 62.5 (41.6) <0.001 35.3 (40.5) 54.2 (46.5) 0.024
Coughing 20.0 (25.4) 26.6 (33.2) 22.2 (27.2) 22.9 (30.0) 0.955 21.4 (28.6) 26.3 (30.4) 0.337
Felt ill 8.0 (19.9) 11.1 (26.7) 23.6 (38.6) 27.7 (40.8) 0.125 13.8 (29.3) 29.4 (41.9) 0.042
Pain killers 28.0 (45.8) 70.0 (46.6) 83.3 (38.0) 77.0 (42.4) <0.001 60.7 (49.1) 79.0 (41.1) 0.038
Nutritional supplements 8.0 (27.6) 6.6 (25.3) 0 6.2 (24.4) 0.613 4.7 (21.4) 6.9 (25.7) 0.606
Feeding tube 0 0 0 0 - 0 0 -
Weight loss 4.0 (20.0) 40.0 (49.8) 54.1 (50.8) 70.8 (45.9) <0.001 34.5 (47.8) 72.0 (45.3) <0.001
Weight gain 28.0 (45.8) 23.3 (43.0) 8.3 (28.2) 6.2 (24.4) 0.035 16.6 (37.4) 11.6 (32.4) 0.453
*Kruskal-Wallis test, **Mann Whitney test. Abbreviations: T, Tumor size; N, Lymph node involvement.
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onstrated significantly worse scores on the swallowing
(HNSW, p < 0.001), speech problems (HNSP, p < 0.001),
social eating (HNSO, p < 0.001), social contact (HNSC,
p < 0.001), teeth (HNTE, p = 0.016), opening mouth
(HNOM, p = 0.001), dry mouth (HNDR, p = 0.004), sticky
saliva (HNSS, p < 0.001), feeling ill (HNFI, p < 0.001),
pain killers (HNPK, p < 0.001) and weight loss (HNWL,
p < 0.001) scales for the cancer group with moderate-
severe pain (Figure 2). In each case, the HNSCC patients
with moderate-severe pain reported greater difficulties
than those with mild or no pain. The group with mild pain
presented scores that were significantly worse than the no
pain group on the senses problems (HNSE, p < 0.001) and
less sexuality (HNSX, p = 0.018) scales.
The intensity of pain was not correlated with the tumor
location (Figure 3); however, the group with larynx tumors
had more patients without pain (p = 0.02). Analyzing the
tumor classification, the group with T1 tumors had more
patients with no pain (p < 0.001), conversely, patients with
T4 tumors indicated a greater intensity of pain (p = 0.003).
The absence of lymph node involvement (N0) revealed
a difference in the percentage of patients without pain
(p = 0.039) (Figure 4).Discussion
This is the first study to evaluate the pain severity among
untreated HNSCC patients and its impact on QoL. We
hypothesized that the intensity of pain in patients with un-
treated HNSCC may be significantly correlated with a
poor QoL. Patients with an advanced-stage tumor showed
higher impairment in functional status (physical, role and
social functioning) and worse symptoms, which is in ac-
cordance with the results of earlier studies [19-21] and
demonstrates the strong correlation between tumor stage
and QoL. Patients with an early-stage tumor had less pain
compared with those who had an advanced-stage tumor.
Regarding tumor site, although more patients with a
tumor in the oral cavity indicated that they had moderate
to severe pain, this difference was not significant and is
difficult to compare with prior results because of the lack
of earlier studies regarding the impact of pain intensity in
pretreatment HNSCC patients.
The HNSCC patients with moderate to severe pain re-
ported higher levels of interference on all of the function-
ing scales, the global QoL and the 4 symptoms (fatigue,
pain, appetite loss and financial difficulties) on the EORTC
QLQ-C30 scales, whereas patients without pain indicated
better results on those scales. Thus, increasing pain is
Figure 1 Mean scores on the EORTC QLQ-C30 for patients with
head and neck cancer according to the level of pain during the
last 24 h (BPI-Average pain intensity). The scales are as follows:
PF, physical functioning; RF, role functioning; EF, emotional
functioning; CF, cognitive functioning; SF, social functioning; QL,
global quality of life; FA, fatigue; NV, nausea/vomiting; DY, dyspnea;
SL, insomnia; AP, appetite loss; CO, constipation; DI, diarrhea; and FI,
financial difficulties. For Figure 1A, higher scores reflect better
functioning; for Figure 1B, higher scores indicate worse functioning.
Significance was determined by Kruskal-Wallis tests.
Figure 2 Mean scores on the EORTC QLQ-H&N35 for patients
with head and neck cancer according to the level of pain during
the last 24 h (BPI-average pain intensity). The scales are as follows:
HNSW, swallowing; HNSE, senses; HNSP, speech; HNSO, social eating;
HNSC, social contact; HNSX, sexuality; HNTE, teeth; HNOM, opening
mouth; HNDR, dry mouth; HNSS, sticky saliva, HNCO, coughing; HNFI,
felt ill; HNPK, pain killers; and HNWL, weight loss. Higher scores indicate
poorer functioning. Significance was determined by Kruskal-Wallis tests.
Figure 3 Correlation between pain intensity (BPI-average pain
intensity) and anatomic sites.
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toms. We found similar results with the EORTC QLQ-
H&N35 because the 11-symptom scales revealed the
worst scores (indicating a high level of problems) for
patients with moderate to severe pain.
In our study, although 66.9% of all patients reported
that they had used analgesic medication for pain con-
trol, the number of patients with pain (59%) remained
high, similar to what was found in an earlier study [22].
While we did not evaluate the analgesic efficacy or regi-
mens, the persistence of pain may reflect the possibility
that it is difficult for patients to report their symptoms
to a physician or may suggest that the patients’ medica-
tion may not be adequately effective. Patients with head
and neck, gastrointestinal and thoracic malignancies
are more likely to experience severe pain compared
with patients with other tumors (52.6%, 33.9% and
30.5%, respectively) [23]. Another study has shown that
58% of HNC patients felt that it was necessary to fill in
the QoL questionnaire before their visit because this
would help them to describe their symptoms to their
doctors [24].Normally, cancer pain is classified into three categories:
pain caused by tumor growth, pain caused by treatment,
and pain unrelated to cancer [25]. Therefore, we excluded
pain caused by treatment because the evaluation of our
patients was performed before of any type of cancer treat-
ment. Tumor growth may cause pain by compressing and
invading surrounding tissues, including muscles, bones,
Figure 4 Correlation between pain intensity (BPI-average pain
intensity) and TN stage. T: tumor size; N: lymph node involvement.
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have a rich blood supply and a large numbers of nerves
that may affect tumor growth and pain [25,26].
A potential limitation of our study might be that we
chose to use the BPI average pain intensity item as the
pain intensity criterion, the study was performed with
moderate sample, and patients’ recruitment was from
one center. However, evaluating the level of pain experi-
enced most frequently is more important for assessing
pain’s interference than evaluating shorter periods with
the highest/lowest pain intensities. Additionally, this cri-
terion is in accordance with other studies [27-30], and
the BPI is recommended by the European Association of
Palliative Care as a pain assessment tool in clinical studies
[31]. As in prior studies, each of the questionnaire scales
demonstrated acceptable reliability, with the exception
of the cognitive functioning scale, which has been
problematic [9,14,32-35].
Although head and neck cancer has the highest preva-
lence of pain [7], clinical health care professionals focus on
the preparation for surgery and issues of the immediate
post-operative period, and the management of symptoms is
neglected [36]. Furthermore, palliative care is initiated only
for end-stage cancer patients, and the mean time from the
initiation of palliative care to death is 21.9 days in head and
neck cancer patients, suggesting that incurable patients
may be referred to palliative care institutions too late. The
majority of patients (85%) admitted to palliative care had
inadequate pain control prior to admission [37]. Therefore,
an evaluation of patients before the initiation of anti-cancer
therapy is important because most studies have focused on
the analysis of pain during or after treatment.
Conclusions
Assessing the quality of life and symptoms before therapy
can direct attention to the most important symptom, such
as pain, and thus, appropriate interventions can improve
QoL outcomes and the response to treatment.Abbreviations
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